Moderna announced positive data from an early-stage study of its mRNA-based combination vaccine for COVID-19 and influenza, showing similar or stronger immune responses compared to standalone vaccines in older adults.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.